Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921659 · ClinicalTrials.gov registry record · Phase 1
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
A Phase 1 study, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02921659 is a Phase 1 study that has completed, run by University of Colorado, Boulder. The registered enrollment target is 30 participants.
The verdict
NCT02921659, a Phase 1 study, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of supplementation with the Nicotinamide Adenine Dinucleotide (NAD+) precursor compound, Nicotinamide Riboside (NR), for improving physiological function (vascular, motor, and cognitive) in healthy middle-aged and older adults.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Niagen™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02921659
The ClinicalTrials.gov registry entry for NCT02921659 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02921659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02921659 about?
NCT02921659 is a clinical study titled "Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults". The purpose of this study is to assess the efficacy of supplementation with the Nicotinamide Adenine Dinucleotide (NAD+) precursor compound, Nicotinamide Riboside (NR), for improving physiological function (vascular, motor, and cognitive) in healthy middle-aged and older adults.
What is the current status of trial NCT02921659?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-04. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02921659?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Niagen™ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02921659?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.